Merck to Host First Quarter 2022 Sales and Earnings Conference Call on April 28



Investors, journalists and the general public can access a live audio webcast of the call via this web link. A replay of the webcast, along with the sales and earnings press release, additional financial information and slides highlighting the results, will be available at

Institutional investors and analysts can participate in the call by dialing (833) 353-0277 or (469) 886-1947 and using the passcode number 6647568. Members of the media are invited to follow the call by dialing (833) 353-0277 or (469) 886-1947 and using the passcode number 6647568. Journalists who wish to ask questions are asked to contact a member of the Media Relations team. Merck media.

About Merck

For more than 125 years, Merck, known as MSD outside the United States and Canada, has been inventing for life, delivering medicines and vaccines for many of the world’s toughest diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patient and population health by improving access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten humans and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company. in the world. For more information, visit and connect with us Twitter, Facebook, instagram, Youtube and LinkedIn.

Merck & Co., Inc., Kenilworth, NJ, USA Forward-Looking Statement

This press release from Merck & Co., Inc., Kenilworth, NJ, USA (the “Company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995 These statements are based on the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and around the world; global trends toward health care cost containment; technological advances, new products and patents obtained by competitors; challenges inherent in developing new products, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and exposure to litigation, including patent litigation, and/or regulatory actions.

The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Other factors that could cause results to differ materially from those described in the forward-looking statements can be found in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 and in other filings by the Company. company with the Securities and Exchange. Commission (SEC) available on the SEC’s website (

See the source version on

Source link


Comments are closed.